Targacept , Inc.  

(Public, NASDAQ:TRGT)   Watch this stock  
Find more results for John C Souza�
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 2.15 - 4.68
Open     -
Vol / Avg. 0.00/67,363.00
Mkt cap 90.10M
P/E     -
Div/yield     -
EPS -0.72
Shares 33.87M
Beta 1.72
Inst. own 76%
May 7, 2015
Q1 2015 Targacept Inc Earnings Release (Estimated)
Mar 6, 2015
Targacept Inc and Catalyst Biosciences Enter Definitive Merger Agreement - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -11253.33% -11862.91%
Operating margin -11371.67% -10805.09%
EBITD margin - -10597.09%
Return on average assets -24.72% -25.30%
Return on average equity -25.51% -26.77%
Employees 19 -
CDP Score - -


Suite 1510, 100 North Main Street
United States - Map
+1-336-4802100 (Phone)
+1-336-4802107 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Targacept, Inc. is a biopharmaceutical company engaged in the development of novel NNR Therapeutics to treat patients suffering from serious nervous system and gastrointestinal or genitourinary diseases and disorders. The Company’s NNR Therapeutics target a class of receptors known as neuronal nicotinic receptors, which it refers to as NNRs which are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity. The Company’s product candidates include: TC-5214, which acts as an antagonist on the a3b4 NNR; TC-1734 (also referred to as AZD3480) which is a wholly owned novel small molecule that modulates the activity of the a4b2 NNR; TC-6499 which is a novel small molecule that modulates the activity of the a3b4 and other NNRs as an agonist; AZD1446 which is a novel small molecule that modulates the activity of the a4b2 NNR; and TC-5619 and TC-6987 which are novel small molecules highly selective for the a7 NNR.

Officers and directors

Stephen Anthony Hill M.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Mauri K. Hodges CPA Chief Financial Officer, Vice President of Finance and Administration, Treasurer
Age: 55
Bio & Compensation  - Reuters
Patrick C. Rock J.D. Senior Vice President, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Scott N. Cullison Vice President - Business Development
Age: 38
Bio & Compensation  - Reuters
John P. Richard Non-Executive Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Charles A. Blixt Esq. Independent Director
Age: 64
Bio & Compensation  - Reuters
Julia R. Brown Independent Director
Age: 67
Bio & Compensation  - Reuters
Errol B. De Souza Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters